Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM21menos65 in transplant-eligible newly diagnosed multiple myeloma
2024-517008-12-00Phase 3Authorised
- Sponsor
- PETHEMA
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isatuximab, iberdomide, bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by PETHEMA. Primary endpoints: MRD negativity improvement for Arm A versus Arm B using B1 definition and MRD negativity non-inferiority for Arm A versus Arm B using B2 definition. Planned start Oct 2024; status: authorised.
02
Drugs
isatuximabiberdomidebortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-517008-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517008-12-00.